TNB-381M

N/A

Report date: 2026/03/19 16:53:35

Base Information

Drug NameTNB-381M
Drug Alias Nameanti-CD3/anti-BCMA bispecific T-cell engager (TeneoBio)bispecific monoclonal antibody (TeneoBio)CD3 targeting bispecific monocloncal antibody (TeneoBio)TNB-381MTNB-382M
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsT lymphocytes stimulantsImmunostimulants +[4] 
TargetsT cell surface glycoprotein CD3Tumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTeneobio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesTeneobio Inc
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A